Can obesity exacerbate hyperinsulinaemia in the presence of the mutation of an insulin receptor gene?

IF 2.2 Q3 ENDOCRINOLOGY & METABOLISM
Clinical Obesity Pub Date : 2023-09-17 DOI:10.1111/cob.12619
Valeria Calcaterra, Gianvincenzo Zuccotti, Alessandra Mari, Fernanda Iafusco, Giovanna Maione, Dario Iafusco, Nadia Tinto
{"title":"Can obesity exacerbate hyperinsulinaemia in the presence of the mutation of an insulin receptor gene?","authors":"Valeria Calcaterra,&nbsp;Gianvincenzo Zuccotti,&nbsp;Alessandra Mari,&nbsp;Fernanda Iafusco,&nbsp;Giovanna Maione,&nbsp;Dario Iafusco,&nbsp;Nadia Tinto","doi":"10.1111/cob.12619","DOIUrl":null,"url":null,"abstract":"<div>\n \n <p>Insulin receptor gene (<i>INSR</i>) mutations are a relatively rare and diverse cause of insulin resistance (IR), typically associated with a lean phenotype. However, we present a unique case of severe obesity and Type A severe IR syndrome in a patient with a heterozygous mutation of the <i>INSR</i> gene. Next Generation Sequencing (NGS) analysis was conducted to identify the genetic variant. A 16-year-old girl with severe obesity (BMI-SDS +2.79) exhibited markedly elevated basal insulin levels (&gt;800 mcU/L). Despite obesity being a known cause of hyperinsulinism, further investigation was pursued due to the severity of hyperinsulinaemia. A heterozygous nucleotide variant at the donor splicing site of intron 13 (c.2682 + 1G &gt; A) of the <i>INSR</i> gene was identified. This mutation was also present in the proband's normal-weight mother and her two younger brothers with obesity. Metformin treatment provided limited benefits, but subsequent liraglutide therapy resulted in weight loss and decreased IR 3 months after initiation. Our findings suggest that obesity can exacerbate hyperinsulinaemia in individuals with an <i>INSR</i> gene mutation. Although INSR signalling defects play a minor role in the aetiology of IR, they should still be considered in the diagnostic pathway, particularly in severe phenotypes. Clinicians should not overlook the possibility of genetic causes in patients with obesity and IR, as they may require personalized management approaches.</p>\n </div>","PeriodicalId":10399,"journal":{"name":"Clinical Obesity","volume":"13 6","pages":""},"PeriodicalIF":2.2000,"publicationDate":"2023-09-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Clinical Obesity","FirstCategoryId":"1085","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/cob.12619","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"ENDOCRINOLOGY & METABOLISM","Score":null,"Total":0}
引用次数: 0

Abstract

Insulin receptor gene (INSR) mutations are a relatively rare and diverse cause of insulin resistance (IR), typically associated with a lean phenotype. However, we present a unique case of severe obesity and Type A severe IR syndrome in a patient with a heterozygous mutation of the INSR gene. Next Generation Sequencing (NGS) analysis was conducted to identify the genetic variant. A 16-year-old girl with severe obesity (BMI-SDS +2.79) exhibited markedly elevated basal insulin levels (>800 mcU/L). Despite obesity being a known cause of hyperinsulinism, further investigation was pursued due to the severity of hyperinsulinaemia. A heterozygous nucleotide variant at the donor splicing site of intron 13 (c.2682 + 1G > A) of the INSR gene was identified. This mutation was also present in the proband's normal-weight mother and her two younger brothers with obesity. Metformin treatment provided limited benefits, but subsequent liraglutide therapy resulted in weight loss and decreased IR 3 months after initiation. Our findings suggest that obesity can exacerbate hyperinsulinaemia in individuals with an INSR gene mutation. Although INSR signalling defects play a minor role in the aetiology of IR, they should still be considered in the diagnostic pathway, particularly in severe phenotypes. Clinicians should not overlook the possibility of genetic causes in patients with obesity and IR, as they may require personalized management approaches.

在胰岛素受体基因突变的情况下,肥胖是否会加重高胰岛素血症?
胰岛素受体基因(INSR)突变是胰岛素抵抗(IR)的一个相对罕见和多样的原因,通常与瘦表型相关。然而,我们提出了一个独特的病例严重肥胖和a型严重IR综合征患者杂合突变的INSR基因。下一代测序(NGS)分析鉴定遗传变异。一名16岁的严重肥胖女孩(BMI-SDS +2.79)表现出明显升高的基础胰岛素水平(>800 mcU/L)。尽管肥胖是已知的高胰岛素血症的原因,但由于高胰岛素血症的严重性,进一步的研究仍在进行中。在INSR基因13内含子(c.2682 + 1G > A)的供体剪接位点上发现了一个杂合核苷酸变异。这种突变也出现在先证者体重正常的母亲和她两个肥胖的弟弟身上。二甲双胍治疗提供有限的益处,但随后的利拉鲁肽治疗导致体重减轻,并在开始治疗3个月后降低了IR。我们的研究结果表明,肥胖可以加剧INSR基因突变个体的高胰岛素血症。尽管INSR信号缺陷在IR的病因学中起着次要作用,但在诊断途径中仍应考虑它们,特别是在严重表型中。临床医生不应忽视肥胖和IR患者的遗传原因的可能性,因为他们可能需要个性化的管理方法。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Clinical Obesity
Clinical Obesity ENDOCRINOLOGY & METABOLISM-
CiteScore
5.90
自引率
3.00%
发文量
59
期刊介绍: Clinical Obesity is an international peer-reviewed journal publishing high quality translational and clinical research papers and reviews focussing on obesity and its co-morbidities. Key areas of interest are: • Patient assessment, classification, diagnosis and prognosis • Drug treatments, clinical trials and supporting research • Bariatric surgery and follow-up issues • Surgical approaches to remove body fat • Pharmacological, dietary and behavioural approaches for weight loss • Clinical physiology • Clinically relevant epidemiology • Psychological aspects of obesity • Co-morbidities • Nursing and care of patients with obesity.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信